AGMB

AgomAb Therapeutics NV
AGMB

32 hedge funds and large institutions have $245M invested in AgomAb Therapeutics NV in 2026 Q1 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

more ownership

Funds ownership: →

Holders
32
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$72.8M
2
+$39.4M
3
+$34.9M
4
TCM
TCG Crossover Management
California
+$29.1M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$22.9M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
EFM
1
EQT Fund Management
Luxembourg
$53.9M
S
2
Sanofi
France
$29.2M
CAM
3
Cormorant Asset Management
Massachusetts
$25.9M
TCM
4
TCG Crossover Management
California
$21.5M
Federated Hermes
5
Federated Hermes
Pennsylvania
$17M
CC
6
Casdin Capital
New York
$16.3M
AP
7
Andera Partners
$16.1M
Fidelity Investments
8
Fidelity Investments
Massachusetts
$15.3M
NCM
9
Nantahala Capital Management
Connecticut
$12.9M
Aberdeen Group
10
Aberdeen Group
United Kingdom
$7.42M
SB
11
Samsara BioCapital
California
$6.29M
PA
12
Perceptive Advisors
New York
$6.29M
SL
13
Siren LLC
Connecticut
$4.31M
LP
14
LMR Partners
United Kingdom
$3.15M
SGM
15
Seven Grand Managers
New York
$2.1M
RG
16
Redmile Group
California
$1.64M
Millennium Management
17
Millennium Management
New York
$999K
P
18
Pfizer
New York
$814K
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
$787K
LCM
20
Laurion Capital Management
New York
$525K
BG
21
Bellevue Group
Switzerland
$525K
SAM
22
Sectoral Asset Management
Quebec, Canada
$477K
Goldman Sachs
23
Goldman Sachs
New York
$375K
Citadel Advisors
24
Citadel Advisors
Florida
$367K
BGM
25
Burkehill Global Management
New York
$367K
1
2